{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% confidence interval was not reached.","groupId":"OG000","lowerLimit":"1.7","upperLimit":"NA","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 100 mg nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 (with 1 week rest). Treatment repeats every 28 days for up to 12 courses/cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, continued treatment is at the discretion of the investigator until evidence of disease progression. Paclitaxel Albumin-Stabilized Nanoparticle Formulation: Given IV","id":"OG000","title":"Treatment (Chemotherapy)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from registration to death due to any cause, assessed up to 3 years","title":"Survival Time","type":"SECONDARY","unitOfMeasure":"months"}